Terms: = Ovarian cancer AND GATA3, HDR, 2625, ENSG00000107485, MGC5445, MGC5199, MGC2346 AND Prognosis
11 results:
1. PRPF6 promotes metastasis and paclitaxel resistance of ovarian cancer via SNHG16/CEBPB/gata3 axis.
Wang H; Zhou Y; Zhang S; Qi YA; Wang M
Oncol Res; 2021; 29(4):275-289. PubMed ID: 37303939
[TBL] [Abstract] [Full Text] [Related]
2. Genomic characterisation of hormone receptor-positive breast cancer arising in very young women.
Luen SJ; Viale G; Nik-Zainal S; Savas P; Kammler R; Dell'Orto P; Biasi O; Degasperi A; Brown LC; Láng I; MacGrogan G; Tondini C; Bellet M; Villa F; Bernardo A; Ciruelos E; Karlsson P; Neven P; Climent M; Müller B; Jochum W; Bonnefoi H; Martino S; Davidson NE; Geyer C; Chia SK; Ingle JN; Coleman R; Solbach C; Thürlimann B; Colleoni M; Coates AS; Goldhirsch A; Fleming GF; Francis PA; Speed TP; Regan MM; Loi S
Ann Oncol; 2023 Apr; 34(4):397-409. PubMed ID: 36709040
[TBL] [Abstract] [Full Text] [Related]
3. Distinct expression and prognostic values of GATA transcription factor family in human ovarian cancer.
Zhou Q; Yang HJ; Zuo MZ; Tao YL
J Ovarian Res; 2022 Apr; 15(1):49. PubMed ID: 35488350
[TBL] [Abstract] [Full Text] [Related]
4. gata3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma.
El-Arabey AA; Denizli M; Kanlikilicer P; Bayraktar R; Ivan C; Rashed M; Kabil N; Ozpolat B; Calin GA; Salama SA; Abd-Allah AR; Sood AK; Lopez-Berestein G
Cell Signal; 2020 Apr; 68():109539. PubMed ID: 31935430
[TBL] [Abstract] [Full Text] [Related]
5. The Clinical Value of PELP1 for Breast cancer: A Comparison with Multiple cancers and Analysis in Breast cancer Subtypes.
Wang X; Tsang JYS; Lee MA; Ni YB; Tong JH; Chan SK; Cheung SY; To KF; Tse GM
Cancer Res Treat; 2019 Apr; 51(2):706-717. PubMed ID: 30134648
[TBL] [Abstract] [Full Text] [Related]
6. Tubo-ovarian Transitional Cell Carcinoma and High-grade Serous Carcinoma Show Subtly Different Immunohistochemistry Profiles.
Magrill J; Karnezis AN; Tessier-Cloutier B; Talhouk A; Kommoss S; Cochrane D; Chow C; Cheng A; Soslow R; Hauptmann S; du Bois A; Pfisterer J; Gilks CB; Huntsman DG; Kommoss F
Int J Gynecol Pathol; 2019 Nov; 38(6):552-561. PubMed ID: 30059451
[TBL] [Abstract] [Full Text] [Related]
7. gata3 as a master regulator and therapeutic target in ovarian high-grade serous carcinoma stem cells.
Chen HJ; Huang RL; Liew PL; Su PH; Chen LY; Weng YC; Chang CC; Wang YC; Chan MW; Lai HC
Int J Cancer; 2018 Dec; 143(12):3106-3119. PubMed ID: 30006927
[TBL] [Abstract] [Full Text] [Related]
8. Simultaneous carcinomas of the breast and ovary: utility of Pax-8, WT-1, and gata3 for distinguishing independent primary tumors from metastases.
Espinosa I; Gallardo A; D'Angelo E; Mozos A; Lerma E; Prat J
Int J Gynecol Pathol; 2015 May; 34(3):257-65. PubMed ID: 25844549
[TBL] [Abstract] [Full Text] [Related]
9. Breast cancer expression of YKL-40 correlates with tumour grade, poor differentiation, and other cancer markers.
Shao R; Cao QJ; Arenas RB; Bigelow C; Bentley B; Yan W
Br J Cancer; 2011 Oct; 105(8):1203-9. PubMed ID: 21934681
[TBL] [Abstract] [Full Text] [Related]
10. Accuracy of ovarian cancer ICD-10 diagnosis in a Danish population-based hospital discharge registry.
Tetsche MS; Nørgaard M; Skriver MV; Andersen ES; Lash TL; Sørensen HT
Eur J Gynaecol Oncol; 2005; 26(3):266-70. PubMed ID: 15991523
[TBL] [Abstract] [Full Text] [Related]
11. Gene expression patterns in ovarian carcinomas.
Schaner ME; Ross DT; Ciaravino G; Sorlie T; Troyanskaya O; Diehn M; Wang YC; Duran GE; Sikic TL; Caldeira S; Skomedal H; Tu IP; Hernandez-Boussard T; Johnson SW; O'Dwyer PJ; Fero MJ; Kristensen GB; Borresen-Dale AL; Hastie T; Tibshirani R; van de Rijn M; Teng NN; Longacre TA; Botstein D; Brown PO; Sikic BI
Mol Biol Cell; 2003 Nov; 14(11):4376-86. PubMed ID: 12960427
[TBL] [Abstract] [Full Text] [Related]
